4D Path Inc. Overview
Pro stress-test →4D Path's patented precision oncology platform is designed to unveil previously hidden data to instantly provide biomarker profiling and stratification directly from H&E whole slide biopsy/resection images only. 4D Path's cloud-based, quantitative approach is intended to eliminate the need for additional molecular tests (e.g., immunohistochemistry, FISH, RNA-Seq, NGS), accelerating complete, actionable and objective insight leading to expedited and democratized precision medicine.
Strategic Profile
Pro stress-test →Led by CEO Jacopo Leonardi, 4D Path has created a platform, the patented Q-Plasia OncoReader (QPOR), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient's response to therapy. In April 2026, Versiti Clinical Trials Services (VCTS) launched a partnership with 4D Path to bring cutting-edge treatment predictive biomarker technology to researchers developing lifesaving, personalized cancer treatments.
Competitive Landscape
Pro stress-test →4D Path specializes in cancer diagnostics using a patented platform that leverages statistical physics and tumor biology and offers an end-to-end automated platform for biomarker typing and prognostication from H&E images, serving pathologists, oncologists, and patients. Primary competitors include digital pathology and AI-powered diagnostic platforms (Proscia, TRIBVN Healthcare, Qritive) that use image-based analysis for cancer diagnosis and workflow automation. 4D Path's differentiation centers on its physics-informed quantification of cell cycle and immune dynamics to predict treatment response, versus general-purpose digital pathology or image analysis solutions.
Industry Context
4D Path Inc. operates in Oncology Drugs.
Key facts
Founded: 2016 · Headquarters: Newton, Massachusetts, US · Employees: 17 · Revenue: N/A · Market cap: N/A